Page 4 - மேகன் குட்டரெஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(2)
XALKORI is the first biomarker-driven therapy for relapsed or refractory ALCL in young people
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for XALKORI
(crizotinib) for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive. The safety and efficacy of XALKORI have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL. ALCL is a rare form of non-Hodgkin lymphoma (NHL) and accounts for approximately 30% of cases of NHL in young people. ....

New York , United States , South Korea , Yael Moss , Chris Boshoff , Bryan Dunn , Meghan Gutierrez , Steve Danehy , A Children Oncology Group Study , Children Oncology Group , Drug Administration , Pfizer Global Product Development , University Of Pennsylvania Children Hospital Philadelphia , Exchange Commission , Pfizer Inc , European Union , European Medicines Agency , Lymphoma Research Foundation , New Drug Application , Chief Development Officer , Pfizer Global Product , Associate Professor , Principal Investigator , Chief Executive Officer , Lymphoma Research , Breakthrough Therapy ,